Activity Overview
This educational activity is an archive of the live presentation held on February 17, 2026.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward hematologist-oncologists, pathologists, advanced practice providers, pharmacists, nurses, and other health care providers involved in the management of patients with AML.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the mechanistic rationale supporting the role of menin inhibitors in AML treatment
- Discuss the potential implications of recent trial evidence and emerging monotherapy/combination therapy trials evaluating menin inhibitors in patients with AML
- Develop individualized care plans for patients with NPM1m and/or KMT2A-r AML based on clinical trial evidence
- Devise strategies to proactively monitor and mitigate treatment-related toxicities and/or treatment resistance in patients with AML receiving menin inhibitors
Naval Daver, MD
Professor of Medicine
The University of Texas MD
Anderson Cancer Center
Director- Leukemia Research
Alliance Program
Houston, TX
Courtney DiNardo, MD
Professor of Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Eunice Wang, MD
Chief, Leukemia Service
Medical Director, Chemotherapy/Infusion Center
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Full faculty information and disclosures are available by reviewing the program workbook, linked here.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login HereAccreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.
Physicians’ Education Resource®, LLC (PER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Physicians’ Education Resource®, LLC has approved this application-based activity for 1.50 ACPE CE hours UAN # 0661-0000-26-001-H01-P. Eligibility for credits requires full attendance, engagement in the live activity, completion and submission of the learner NABP ID # and month and day of birth, activity pre/post-session questions, and the post activity evaluation.
Acknowledgment of Commercial Support
This activity is supported by educational grants from Janssen Scientific Affairs, LLC; Kura Oncology; and Syndax Pharmaceuticals.
